Anika Therapeutics (ANIK) investor relations material

Executive summary

• Q1 2026 revenue grew 13% year-over-year to $29.6 million, driven by strong Commercial and OEM Channel performance, with Regenerative Solutions and international OA Pain Management contributing significantly.

• Gross margin improved to 64% from 56%, reflecting operational improvements, manufacturing productivity, and favorable product mix.

• Adjusted EBITDA reached $4.3 million, up by more than $4 million year-over-year, highlighting improved profitability and operating leverage.

• Strategic focus centered on commercial channel growth, HA-based innovation, operational execution, and transformation, with leadership changes and divestitures completed.

• Integrity product adoption accelerated, with U.S. procedures up 35% year-over-year and new surgeon adoption growing at a double-digit rate.

Financial highlights

• Commercial Channel revenue increased 12% to $12.6 million; OEM Channel revenue rose 14% to $17 million.

• International OA Pain Management revenue rose 9% to $8.9 million, driven by Monovisc and Cingal.

• Gross profit was $19.0 million, up from $14.7 million year-over-year.

• Operating expenses totaled $24.5 million, including $4.9 million in one-time severance costs.

• Adjusted net income from continuing operations was $3.8 million, or $0.27 per diluted share.

Outlook and guidance

• Fiscal 2026 revenue guidance maintained at $114–$122.5 million, representing 1%–9% growth year-over-year.

• Commercial Channel expected to grow 10%–20% ($53–$58 million); OEM Channel projected flat to modestly lower.

• Adjusted EBITDA guidance remains at 5%–10% of revenue.

• U.S. launches for Hyalofast and Cingal pending FDA review; $3 million 2027 U.S. revenue target for Hyalofast built into assumptions.

• Restructuring actions expected to be completed by Q2 2026.